SHARPE·IQStart free
Menu
TodayResearchEarningsToolsPricingSign in
IMUX reported Third Quarter 2026 results. The price and volatility reaction is pending.
IMUXearnings

Earnings reactions, page 2

Immunic, Inc. (IMUX) Q3 FY2026 earnings

November 13, 2026 · SharpeIQ Research Desk

Reported results

  • Total operating expenses were $43.4 million for the three months ended September 30, 2026.
  • Research and Development (R&D) expenses were $23.9 million for the three months ended September 30, 2026.
  • General and Administrative (G&A) expenses were $19.4 million for the three months ended September 30, 2026.
  • Net loss was $42.3 million, or $0.99 per basic and diluted share, for the three months ended September 30, 2026.
  • Interest income was $1.1 million for the three months ended September 30, 2026.

Guidance

  • Immunic expects that its cash and cash equivalents of $132.0 million will be sufficient to fund its operations into late 2027.
  • Top-line data from the Phase 3 ENSURE-1 and ENSURE-2 trials is expected in December 2026.
  • First-patient-enrolled for the Phase 3 PROTECT-MS trial is expected in the first half of 2027.
  • If ENSURE results are positive, Immunic plans to submit an NDA in the United States in mid-2027, with a targeted potential regulatory approval date in 2028.

Price and volatility reaction

Source

The figures above come from the earnings release the company filed with the SEC on 2026-11-13 (8-K, Item 2.02). Read the original filing on sec.gov.

See this live in SharpeIQ

IV rank, historical IV and the single-ticker tools. The scanner and AI research are paid plans.

Open IV Rank →